GALECTIN THERAPEUTICS INC 8-K

What Happened
Galectin Therapeutics, Inc. (GALT) filed a Form 8‑K on January 12, 2026, disclosing that director Marc Rubin resigned from the company’s Board of Directors effective January 10, 2026. The filing states Mr. Rubin’s resignation was not the result of any disagreement with the company on matters relating to its operations, policies or practices.

Key Details

• Filing: Form 8‑K submitted January 12, 2026 (Item 5.02).
• Resignation effective date: January 10, 2026.
• Director: Marc Rubin.
• Reason: Not due to any disagreement with the company’s operations, policies or practices (as stated in the filing).

Why It Matters
Board departures can affect corporate governance and investor confidence. Because the company explicitly says the resignation was not due to a disagreement, there is no indication of governance conflict from this filing. Investors should watch for any follow-up disclosures about a board replacement or changes to committee memberships, but the 8‑K does not indicate any immediate financial impact.